Loading
companiesCompany
ImmuneOncia Therapeutics
ImmuneOncia Therapeutics is a South Korea-based biotechnology company running 2 late-stage cancer trials of IMC-001 in peripheral T-cell lymphomas.
Also called: ImmuneOncia Therapeutics Inc.
Overview
ImmuneOncia Therapeutics, based in Yongin-si, South Korea, is a biotechnology company. ImmuneOncia Therapeutics develops immuno-oncology antibody drugs, stating its aim is to bring Korea's first immuno-oncology drug to market. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing IMC-001 in peripheral T-cell lymphomas. The largest, NCT06365840 (A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumour), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyMundipharma
Shares Pivotal (registrational) trial, Clinical trial, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- CompanyCyclacel Pharmaceuticals